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Abstract objective To assess the long-term effects of population-level HSV-2 infection on HIV incidence.
methods Data from a population-based cohort in south-western Uganda were used to estimate HIV
incidence from 1990 to 2007. Stored blood samples were tested for HSV-2, and the impact of HSV-2
prevalence and incidence on HIV incidence was estimated by calculating population attributable
fractions (PAFs). The association between population-level annual HIV incidence and annual HSV-2
incidence/prevalence was analysed using linear regression.
results HIV incidence declined over time among men, from 8.72/1000 person-years (pyr) in 1990
to 4.85/1000 pyr in 2007 (P-trend <0.001). In contrast, there was no decline in HIV incidence among
women (4.86/1000 pyr in 1990 to 6.74/1000 pyr in 2007, P-trend = 0.18). PAFs of incident HIV
attributable to HSV-2 were high (60% in males; 70% in females). There was no evidence of an
association between long-term trends in HIV incidence and HSV-2 prevalence or incidence.
conclusion Assuming a causal relationship, a substantial proportion of new HIV infections in this
population are attributable to HSV-2. The study did not find an effect of HSV-2 prevalence/incidence
on trends in HIV incidence. HIV incidence did not vary much during the study period. This may
partly explain the lack of association.
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Introduction
Few African population-based studies have reported
trends in HIV incidence over time (Shafer et al. 2008).
Direct estimates of HIV incidence are useful measures of
progress in HIV prevention, as unlike HIV prevalence
estimates, they do not depend on treatment and mortal-
ity parameters (Mahy et al. 2009; Joint United Nations
Programme on HIV/AIDS (UNAIDS) & The Global
HIV/AIDS Program (GHAP) The World Bank 2009).
However, direct determination of incidence is expensive
and logistically difficult. In this study, we report results
from a long-term population-based cohort in rural
south-western Uganda to directly estimate incidence
from 1990 to 2007 and to examine the association
between HSV-2 infection and risk of HIV acquisition in
this population.
Clinical, biological and epidemiological evidence sug-
gests that HSV-2 infection increases the risk of HIV
acquisition (Glynn et al. 2009) and transmission (Shacker
et al. 2002; Nagot et al. 2007; Zuckerman et al. 2007;
Baeten et al. 2008; Dunne et al. 2008; Delany et al.
2009) at an individual level, through clinical and subclin-
ical reactivations of HSV-2. Randomised controlled trials
of HSV-2 suppressive treatment have not found an effect
on HIV incidence rate. However, lack of effect may have
been the result of poor adherence to study drug, subopti-
mal drug concentrations at the given dose, or ineffective
study drug (Celum et al. 2008; Watson-Jones et al. 2008;
Zhu et al. 2009). To our knowledge, there have been no
empirical studies of the association between HIV inci-
dence and HSV-2 infection at population level. Mathe-
matical models have estimated that, in a mature HIV
epidemic, HSV-2 infection may account for 25–50% of
new HIV infections (Freeman et al. 2007; Abu-Raddad
et al. 2008), that a hypothetical prophylactic HSV-2 vac-
cine may reduce HIV incidence by 30–40% after
20 years (Freeman et al. 2009), and that long-term HSV-
2 suppressive therapy may reduce risk of onward trans-
mission of HIV and reduce HIV incidence by 30%
(White et al. 2008). These studies reflect the potential of
effective HSV-2 control on HIV incidence. In this study,
we estimate the proportion of new HIV infections attrib-
utable to HSV-2 infection and analyse the association
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between population-level trends in HIV incidence and
HSV-2 prevalence and incidence.
Methods
Study population
Details of the cohort have been published previously
(Shafer et al. 2008). Briefly, the study is located in a sub-
county in south-western Uganda, in which household sur-
veys of socio-demographic and behavioural
characteristics, as well as HIV serostatus of all consenting
residents aged 13 years and above have been conducted
annually since 1989. The cohort was initially comprised
of about 10 000 people residing in 15 neighbouring vil-
lages (the old villages) but was expanded at the 1999/
2000 survey to approximately 18 000 people in 25 vil-
lages. The average annual participation rate is about 60–
65%. Community sensitisation activities precede each
survey round, including local council briefings and village
meetings. All households are visited by, in turn, the map-
ping, census and survey teams. Consenting residents are
interviewed at home in the local language by trained sur-
vey staff and provide a blood sample for HIV testing.
Each annual survey begins in November and ends in
October the following year. This study used data and
stored blood samples collected between 1990 and 2007
from participants aged 13–59 years. For simplicity, we
denote survey rounds by the year in which the survey
ends (e.g. data collected from November 1989 to Octo-
ber 1990 are denoted 1990).
Laboratory methods
HIV infection at each visit was determined using two
parallel ELISA tests (Wellcozyme HIV-1 recombinant VK
56/57, Murex Biotech, Dartford, UK; and Recombigen
HIV-1/2, Trinity Biotech, Galway, Ireland) confirmed
with Western blot in case of first-time positives or discor-
dant ELISA (Van der Paal et al. 2007). HSV-2 was deter-
mined using the Kalon ELISA (Kalon Biological, UK)
with cut-off optical density for a positive result at 1.5
(Biraro et al. 2011). To minimise unnecessary testing, all
samples were tested for HSV-2 at key survey rounds
(1990, 1994, 2000, 2007). Samples from participants
testing positive at these rounds were back-tested in the
previous rounds until a negative result was detected.
Statistical methods
Analyses were restricted to the 15 villages with data from
the whole follow-up to allow estimation of changes over
time. An a priori decision was taken to stratify analyses
by gender because incidence rates and risk factors for
HIV infection differ by sex. Annual HIV incidence rates
were estimated from 1990 to 2007. Participants were
censored at the earliest of the last HIV-negative test or
estimated date of seroconversion (estimated as the mid-
point of the last negative and first positive result). Both
observed and smoothed incidence rates were plotted for
easier visual interpretation of trends. Smoothing was car-
ried out using the locally weighted scatterplot smoothing
(LOWESS) procedure (Cleveland & Devlin 1988).
HSV-2 test results were available from 48.9% of the
eligible resident population overall, and from 48.2%,
41.9%, 50.6% and 53.9% in 1990, 1994, 2000 and
2007, respectively. To minimise bias due to missing data,
HSV-2 prevalence was estimated using multiple imputa-
tion (Sterne et al. 2009). Data were assumed to be ‘miss-
ing at random’ as HSV-2 data were missing mainly
because participants chose not to provide a blood sample
due to study fatigue, due to absence from home, or lack
of availability of samples (Wagner et al. 1994; Kamali
et al. 1999). Variables included in the multiple imputa-
tion were sex, age, marital status, HIV status and
observed HSV-2 status results. These were selected
because they were the main independent predictor vari-
ables for HSV-2 infection that were available in the data
set. Annual HSV-2 incidence rates were calculated using
an approach similar to that for HIV incidence described
above, on the basis of actual HSV-2 test result, rather
than longitudinal or multiple imputation. However,
unduly long intervals between the last negative and first
positive results will result in imprecise estimated dates of
seroconversion and may cause an artificially high estimate
of incidence in the periods corresponding to the mid-
points. To examine this potential bias, sensitivity analyses
were conducted by comparing incidence estimates from
analyses including all participants irrespective of the
length of the interval between last negative and first posi-
tive test with estimates from analyses limited to partici-
pants with intervals less than 4, 3 and 2 years,
respectively. Estimates for annual HSV-2 incidence were
similar, so all participants with interviews of up to
4 years retained in the analysis.
To study the effect of HSV-2 infection on HIV inci-
dence, crude and adjusted incidence rate ratios (IRR) and
95%CI were estimated using Poisson regression. A hier-
archical modelling approach was used (Victora et al.
1997). An a priori decision was made to adjust all analy-
ses for time period and age group, as risk of HIV inci-
dence is likely to be associated with these factors. Four
time periods were defined. These were two 5-year periods
in the 1990s when HIV prevalence/incidence was known
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to have declined in this population and two periods in
the 2000s when declines in HIV prevalence/incidence
were no longer observed (Shafer et al. 2008). The time
periods are 1990–1994, 1995–1999, 2000–2004 and
2005–2007. P-values for association were estimated using
the likelihood ratio test. As the primary exposure of
interest, HSV-2 was retained in the model irrespective of
the level of association with HIV incidence. Initially, the
association between HIV and socio-demographic factors
was analysed, and factors with P < 0.15 were fitted in a
core socio-demographic model and retained if they
remained independently associated with HIV (P < 0.15).
Subsequently, each behavioural factor was adjusted for
this core socio-demographic model. Behavioural factors
in the model were then removed one at a time and
retained if significant at P < 0.15. Finally, as the primary
exposure of interest, HSV-2 was added into the model
and other factors retained if independently associated
with HIV (P < 0.15). Factors that remained with
P < 0.05 in the final model were considered to be inde-
pendently associated with incident HIV infection. Demo-
graphic factors included in the analysis were period in
time, age, level of education, marital status and religion;
whereas behavioural factors were age at first sex, number
of lifetime sexual partners, number of sexual partners in
the last year. As risky behaviour is known to increase risk
of HIV incidence, risk factor analysis for behavioural
variables was limited to sexually active participants to
compare risk for different levels of risky behaviour, but
all participants were included in the final model.
To estimate the impact of HSV-2 on HIV incidence at
the population level, population attributable fractions
(PAFs) were estimated using adjusted incidence rate ratios
(aIRR) for HSV-2 from Poisson regression models for
HIV incidence adjusting for the effect of other factors
that were found to be independently associated with HIV
incidence at the individual level (Brady 1998). These fac-
tors included increasing age, being an internal migrant,
not being Muslim, being presently or previously married,
and being HSV-2 infected, as well as time period (men
only) and belonging to tribe other than Muganda
(women only). PAFs were estimated separately by sex
and age group. The age group cut-off was defined as the
median age at HIV seroconversion to maximise statistical
power. The median age at HIV seroconversion was found
to be 28.7 years overall and 31 in men and 26 in women.
As both HIV and HSV-2 are sexually transmitted infec-
tions and may be acquired simultaneously, PAFs were
estimated for incident HSV-2 (i.e. seroconversion to
HSV-2 in the same time period as HIV seroconversion)
and prevalent HSV-2 (HSV-2 infection prior to HIV
seroconversion), separately.
Analysis for risk of acquisition examined the effect of
HSV-2 prevalence/incidence on HIV incidence in the same
gender, whereas analysis for risk of transmission examined
effect HSV-2 prevalence/incidence from one gender on
HIV incidence in the opposite gender. The association of
population-level annual HIV incidence with annual HSV-
2 incidence/prevalence was analysed by calculating crude
and adjusted regression coefficients and 95% confidence
intervals using linear regression. The effect of HSV-2 on
HIV incidence was adjusted for population-level measures
of the other factors that were found to be independently
associated with HIV incidence at the individual level. In
this population, almost all HIV transmission occurs
through heterosexual contact (White et al. 2007). There-
fore, the effect of HSV-2 on HIV acquisition in the popu-
lation was investigated by examining how HIV incidence
in a given gender is related to HSV-2 in the same gender.
The effect of HSV-2 on HIV transmission was investigated
by examining how HIV incidence in one gender is influ-
enced by HSV-2 in the opposite gender. As HSV-2 is more
transmissible than HIV, it was hypothesised that at a pop-
ulation level, changes in HSV-2 incidence are likely to pre-
cede changes in HIV incidence. For this reason, analyses
examined both the correlation between annual HIV inci-
dence and HSV-2 infection in the same year, and correla-
tions between HIV incidence and HSV-2 infection 1 year
and 3 years previously, respectively.
Ethics approvals
The study obtained approval from the science and ethics
review committees of the London School of Hygiene and
Tropical Medicine, the Uganda Virus Research Institute and
the Uganda National Council for Science and Technology.
Results
Study population
Between January 1990 and December 2007, 17 118
participants aged 13–59 years were censused as resident
in the study population on at least one annual survey. Of
these, 14 016 (81.9%) had one or more HIV test results,
of whom 13 021 (92.9%) were HIV negative at their first
visit with known HIV status and were eligible for inclu-
sion in HIV incidence analyses. Of these eligible partici-
pants, 10 137 (77.9%) had subsequent visits with known
HIV status and were included in the incidence analysis.
The median follow-up time was 4.2 years (range 0.2–
18.0 years) and was similar in men and women
(4.6 years vs. 4.1 years; P = 0.29). Table 1 shows further
details of the study population by gender, period and age.
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Among the 13 021 HIV-negative participants, those
with follow-up HIV data and thus included were more
likely to be female, were slightly younger, were more
likely to be Muslim, to be never married, and to be HSV-
2 seropositive than those without follow-up HIV data.
Overall HIV incidence
Of the 10 137 participants, 387 seroconverted for HIV
during follow-up (incidence rate = 6.02/1000 pyr, 95%
CI: 5.45–6.65/1000 pyr). HIV incidence was slightly
higher in women than in men (6.48/1000 pyr vs. 5.51/
1000 pyr; IRR = 1.18, 95% CI: 0.96–1.44). The median
age at seroconversion was 28.7 years (range 14.5–
59.6 years) and was higher in men than in women (31.1
vs. 26.0 years; P < 0.001). Among HIV seroconverters,
the median time to seroconversion was 5.6 years (range
0.4–17.6 years) and was slightly longer in men than in
women (5.6 vs. 4.4 years; P = 0.04). The median time
between last negative and first positive test was 1.3 years
(range 0.2–18.0 years).
Trends in HIV incidence
The estimated HIV incidence among men declined fairly
steadily from 8.72/1000 pyr in 1990 to 4.85/1000 pyr in
2007 (P-trend <0.001; Figure 1), and this was reflected in
all age groups. There was less evidence of a decline in inci-
dence among women, that is, 4.86/1000 pyr in 1990 to
6.74/1000 pyr in 2007 (P-trend = 0.18; Figure 2).
Association between HIV incidence and HSV-2
prevalence/incidence
HIV incidence fell over the years (as compared to 1990–
1994, IRR = 1.16 [95% CI: 0.79–1.70] in 1995–1999,
IRR = 0.78 [95% CI: 0.52–1.19] in 2000–2004,
IRR = 0.50 [95% CI: 0.27–0.92] in 2005–2007,
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Figure 1 HIV incidence HSV-2 incidence
and prevalence in men.
Table 1 Prevalence and incidence of HSV-2 and incidence of
HIV in men and women
HSV-2 Prevalence
(Number at risk)
HSV-2
Incidence
cases/pyr
HIV incidence
cases/pyr
Men
Period
1990–1994 41.0 (1083) 78/3404 45/6984
1995–1999 38.9 (1067) 94/4662 62/8851
2000–2004 28.5 (1485) 109/4933 44/9550
2005–2007 30.8 (1539) 60/2107 16/4945
Age
13–19 10.2 (2205) 120/7793 10/11 261
20–24 20.7 (641) 80/2738 36/4554
25–29 42.7 (480) 57/1649 46/3415
30–59 64.6 (1848) 84/2926 75/11 099
Women
Period
1990–1994 62.4 (1118) 104/2420 61/7656
1995–1999 55.3 (1303) 132/3385 57/9573
2000–2004 48.0 (1799) 146/4103 71/10 827
2005–2007 50.5 (2060) 70/1878 31/5900
Age
13–19 15.3 (2197) 193/6601 58/10 104
20–24 50.9 (827) 125/2176 59/4962
25–29 66.5 (713) 63/1114 39/4108
30–59 82.2 (2543) 71/1894 64/14 781
1260 © 2013 John Wiley & Sons Ltd
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P = 0.02), increased with age (as compared to aged
13–19 years, IRR = 6.07 [95% CI: 2.93–12.55] among
those aged 20–24, IRR = 9.79 [95% CI: 4.62–20.76]
among those aged 25–29, IRR = 4.59 [95% CI: 2.14–
9.84] among those aged 30–59, P < 0.001), and with
being an internal migrant within the study villages
(IRR = 1.57 [95% CI: 1.09–2.26], P = 0.03, i.e. as com-
pared to being a usual resident). Being Muslim was pro-
tective (IRR = 0.37 [95% CI: 0.22–0.63], P < 0.001), as
was being presently or previously married, that is, as
compared to having never been married (IRR = 1.05
[95% CI: 0.65–1.70] among those married for 1 + year,
IRR = 2.42 [95% CI: 1.44–4.08] among those previously
married) and having HSV-2 infection (IRR = 4.03 [95%
CI: 1.71–9.50] for incident HSV-2, IRR = 3.01 [95% CI:
1.83–4.94] for prevalent HSV-2).
In women, HIV incidence fell with increasing age (as
compared to aged 13–19 years, IRR = 1.48 [95% CI:
0.99–2.19] among those aged 20–24, IRR = 1.17 [95%
CI: 0.73–1.86] among those aged 25–29 and IRR = 0.52
[95% CI: 0.33–0.82] among those aged 30–59,
P < 0.001) was associated with being an internal migrant
(IRR = 1.97 [95% CI: 1.42–2.73], P < 0.001), belonging
to tribe other than Muganda (IRR = 1.41 [95% CI:
1.03–1.91], P = 0.03), not being Muslim (IRR = 0.59
[95% CI: 0.41–0.86], P = 0.004), being currently or pre-
viously married (IRR = 1.79 [95% CI: 0.88–3.64] for
currently married and IRR = 0.86 [95% CI: 0.56–1.34]
for previously married, P = 0.01) and being HVS-2 posi-
tive (IRR = 7.25[95% CI: 3.77–13.95] for incident HSV-
2 and IRR = 3.71 [95% CI: 2.23–6.18] for prevalent
HSV-2, P < 0.001).
Fraction of incident HIV attributable to HSV-2
Population attributable fractions by calendar period and
gender ranged between 2–16% for incident HSV-2 infec-
tion and 36–65% for prevalent HSV-2 infection
(Table 2). PAFs were generally higher for younger age
groups (<28 years) than older age groups, that is, 28 year
and above (55–79% vs. 34–70%, respectively) but were
similar in men and women. In both men and women,
PAFs were generally lower for incident HSV-2 than for
prevalent HSV-2 infection.
Association between annual HIV incidence and annual
HSV-2 prevalence/incidence
There was little evidence of an effect of either annual
HSV-2 incidence or prevalence in the previous year or
3 years previously, on annual HIV incidence (Table 3),
although there was some evidence that HIV incidence in
men was associated with HSV-2 incidence in women
3 years previously; and that HIV incidence in women
was associated with HSV-2 incidence in both men and
women in the previous year (Table 3). However, after
adjusting for other population-level factors, that is, age,
being an internal migrant, not being Muslim, being
presently or previously married, and being HSV-2
infected, as well as time period (men only) and belonging
to tribe other than Muganda (women only), HIV inci-
dence in men was only associated with overall HSV-2
incidence (regression coefficient 0.1, 95%CI: 0.03–0.2,
P = 0.04), and HIV incidence in women was only associ-
ated with HSV-2 incidence in men in the previous year
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Figure 2 HIV incidence HSV-2 incidence
and prevalence in women.
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(regression coefficient 0.1, 95%CI: 0.02–0.2, P = 0.04;
Table 3).
Discussion
Ours is the first study in sub-Saharan Africa to have
long-term, annual data on HSV-2 and HIV infections,
enabling analysis of effects of HSV-2 on HIV incidence in
relation to time, a subject that is otherwise often studied
using mathematical models because of lack of actual
observed data.
Individual-level association between HIV incidence and
HSV-2 prevalence/incidence
In keeping with previous observational epidemiological
studies, HIV seroconversion was independently associated
with HSV-2 infection, and risk was higher for incident
Table 2 Population attributable fraction of HIV incidence attributable to HSV-2 infection, by age, sex and period*
PAFs [95% CI]
1990–1994 1995–1999 2000–2004 2005–2007 Overall
Men and women
Aged below 28 years
Incident 3 16 9 15 10
Prevalent 51 60 68 52 62
Overall 55 [2, 79] 79 [54, 90] 79 [59, 89] 75 [12, 93] 75 [63, 83]
Aged 28 years and above
Incident 0 21 1 20 6
Prevalent 52 7 69 20 30
Overall 52 [54, 85] 4 [NE] 70 [0, 91] 35 [105, 79] 34 [2, 56]
Men and women, overall
Incident 2 15 10 16 12
Prevalent 47 39 65 36 51
Overall 50 [10, 72] 55 [30, 72] 75 [56, 85] 57 [1, 81] 64 [51, 73]
Men only
Aged below 30 years
Incident 13 9 1 26 6
Prevalent 18 67 71 41 61
Overall 39 [111, 82] 76 [32, 92] 67 [14, 87] 73 [≤10, 99] 68 [41, 82]
Aged 30 years and above
Incident 1 30 1† 2 9
Prevalent 63 6 52† 33 35
Overall 63 [138, 94] 18 [52, 56] 39 [65, 77] 33 [313, 89] 41 [2, 66]
Men, overall
Incident 10 18 1 10 7
Prevalent 39 44 68 43 53
Overall 48 [35, 80] 62 [26, 80] 64 [24, 83] 56 [≤10, 100] 61 [40, 74]
Women only
Aged below 25 years
Incident 1 12 11 18 10
Prevalent 57 57 71 38 64
Overall 54 [18, 82] 72 [25, 89] 86 [60, 95] 70 [31, 93] 76 [59, 86]
Aged 25 years and above
Incident 1 25 15 18 17
Prevalent 42 11 62 21 30
Overall 42 [146, 86] 9 [NE] 74 [56, 96] 32 [186, 84] 40 [9, 67]
Women, Overall
Incident 2 15 15 19 14
Prevalent 46 41 66 35 53
Overall 44 [14, 73] 57 [18, 77] 82 [58, 92] 59 [11, 85] 67 [52, 78]
NE, Note estimated because computationally minute.
*Adjusted by residence status, religion, marital status and age (if not categorised by age).
†Not adjusted by marital status as all HIV seroconverters were married.
1262 © 2013 John Wiley & Sons Ltd
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than for prevalent HSV-2 (del Mar Pujades Rodrıguez
et al. 2002; Reynolds et al. 2003; Freeman et al. 2006;
Glynn et al. 2009).
Fraction of incident HIV attributable to HSV-2
Assuming a causal relationship between HSV-2 infection
and HIV incidence, the estimated fraction of incident
HIV attributable to HSV-2 infection in this population
where HIV prevalence ranged between 6.2% and 8.5% is
high (Shafer et al. 2008). Overall, PAFs ranged between
50% and 75% and were higher for prevalent than for
incident HSV-2, were higher for younger than for older
people, but were similar in women and men. PAFs were
persistently high and did not show any pattern of decline
or increase with time. PAFs are a function of the propor-
tion of the population with the risk factor being investi-
gated. This explains the higher PAFs for prevalent HSV-2
as the proportion of prevalent HSV-2 in the population is
higher than that for incident HSV-2. The frequency of
HSV-2 reactivations is known to decrease over time, and
this coupled with the higher incidence in the young peo-
ple may explain the lower PAFS in older people (Bened-
etti et al. 1999).
Population attributable fractions in other population-
based studies vary, from 15% to 21% for genital ulcer
disease in Rakai district, Uganda (Gray et al. 1999),
and 59–65% for HSV-2 infection in Mwanza region,
Tanzania (Todd et al. 2006). The low PAFs in the Ra-
kai study may be partly due to misclassification of
HSV-2 positives without GUD as HSV-2 negative. The
high PAFs in Mwanza are likely to reflect more sensi-
tive testing for HSV-2, although in contrast the PAFs
from Mwanza were higher in men than in women.
Studies using mathematical models using data from
Cotonou, Benin and Kisumu, Kenya have estimated that
the proportion of incident HIV attributable to HSV-2
increases with time as the HIV epidemic unfolds and
estimated PAFs ranging between 25% and 50% in
mature epidemics (Freeman et al. 2007; Abu-Raddad
et al. 2008).
Despite the likely importance of HSV-2 as a driver of
the HIV epidemic, at present, there is no effective or fea-
sible HSV-2 intervention against HIV acquisition. How-
ever, there is some evidence from mathematical
modelling studies that an effective population-wide inter-
vention against HSV-2 may reduce HIV incidence rates
(White et al. 2008; Freeman et al. 2009). There is need
Table 3 Association between annual HIV incidence and HSV-2 incidence and prevalence
Previous year
Coefficient – crude
[95% CI]†
Previous year
Coefficient – adjusted
[95% CI]†
Three years previously
Coefficient – crude
[95% CI] †
Three years
previously
Coefficient – adjusted
[95% CI] †
Men
HSV-2 incidence in men 0.1 [0.1, 0.04] 0.1 [0.2, 0.03 ] 0.1 [0.04, 0.2] 0.1 [0.004, 0.3]
HSV-2 incidence in women 0.1 [0.1, 0.02] 0.04 [0.1, 0.05] 0.1 [0.01, 0.1],
P = 0.05
0.1 [0.01, 0.2]
HSV-2 incidence overall 0.1 [0.1, 0.02] 0.1 [0.2, 0.04] 0.1 [0.02, 0.2] 0.1 [0.03, 0.2],
P = 0.04
HSV-2 prevalence in men 0.5 [0.1, 0.9] 0.4 [0.2, 0.9] 0.4 [0.1, 0.8] 0.1 [0.5, 0.7]
HSV-2 prevalence in women 0.1 [0.2, 0.5] 0.1 [0.3, 0.6] 0.3 [0.1, 0.6] 0.3 [0.2, 0.8]
HSV-2 prevalence overall 0.1 [0.3, 0.1] 0.02 [0.4, 0.4] 0.0 [0.2, 0.2] 0.1 [0.4, 0.6]
Women
HSV-2 incidence in men 0.1 [0.01, 0.1], P = 0.06 0.1 [0.02, 0.2],
P = 0.04
0.1 [0, 0.2] 0.1 [0.2, 0.1]
HSV-2 incidence in women 0.1 [0.02, 0.1], P = 0.01 0.1 [0.01, 0.1] 0. 0 [0.1, 0.1] 0.04 [0.1, 0.03]
HSV-2 incidence overall 0.1 [0.02, 0.1], P = 0.02 0.1 [0.002, 0.2] 0. 0 [0.1, 0.1] 0.02 [0.1, 0.1]
HSV-2 prevalence in men 0.1 [0.5, 0.3] 0.4 [0.9, 0.1] 0.2 [0.2, 0.6] 0.1 [0.4, 0.5]
HSV-2 prevalence in women 0.2 [0.5, 0.1] 0.2 [0.6, 0.1] 0.2 [0.1, 0.6] 0.2 [0.2, 0.6]
HSV-2 prevalence overall 0.001 [0.2, 0.2] 0.1 [0.3, 0.4] 0.2 [0.3, 0.02],
P = 0.04
0.1 [0.4, 0.3]
†P-value >0.05 if not indicated.
Adjusted by median age, per cent of population that were internal migrants, per cent that were not Muslim, per cent that had ever
been married and per cent that were HSV-2 infected.
Each coefficient represents the direction and magnitude of effect of HSV-2 prevalence/incidence on HIV incidence. For example, an
increase of 1/1000 pyr in HSV-2 incidence in men resulted in a 0.1/1000 pyr increase in the HIV incidence in women.
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for research on effective HSV-2 interventions that can be
used for HIV prevention. These might include higher-
dose acyclovir or valacyclovir or a vaccine. In addition,
further studies into the biological mechanisms by which
HSV-2 may increase HIV risk are necessary.
Relative trends of HIV incidence and HSV-2 prevalence/
incidence
From the mid-1990s, HSV-2 incidence increased in both
sexes, while HIV incidence continued to decrease in
men and remained roughly constant in women. This
divergence may reflect differences in transmissibility and
risk factors for these two STIs. HSV-2 is a good bio-
marker of risky sexual behaviour, particularly among
young adults (Cowan et al. 1994; Obasi et al. 1999).
The lack of decrease in HSV-2 incidence therefore sug-
gests persistent risky sexual behaviour. Increases in
HSV-2 incidence in the face of declining HIV incidence
may have been because HSV-2 is more easily transmissi-
ble and had higher background prevalence than HIV,
therefore a modest increase in risk behaviour may have
resulted into reversal of a declining trend in HSV-2 inci-
dence without substantially changing trend of HIV inci-
dence. In addition, the prevalence of curable STIs may
have decreased with increased availability of syndromic
STI treatment in the population (Morgan et al. 2001).
This may have reduced HIV incidence without affecting
HSV-2 incidence.
At population level, an effective intervention for both
HIV and HSV-2 is likely to achieve reductions in HIV
incidence ahead of reductions in HSV-2 because of
higher transmissibility and higher background prevalence
of HSV-2. For the same reason, increase in risky sexual
behaviour is likely to manifest as increase in HSV-2
incidence before increase in HIV incidence, and HIV
incidence may not increase if the risky behaviour is
short-lived. Furthermore, even for an intervention with
similar impact of both infections, a change in HSV-2
incidence is likely to be detected earlier because HSV-2
has a higher background incidence rate as compared to
HIV.
Only one study from Africa has compared trends in
prevalence of HIV and HSV-2. The study tested stored
blood samples from population-based controls in TB
case–control studies from 1988 to 2005 in Karonga dis-
trict in northern Malawi. In the respective study peri-
ods, HIV prevalence increased from 4.0% to 12.3% in
men and 4.3% to 16.3% in women. In contrast, HSV-2
prevalence remained roughly constant in men at around
30% and in women at around 40–50% (Glynn et al.
2008).
Population-level association between HIV incidence and
HSV-2 prevalence/incidence
Overall, there was little evidence for an association
between annual HIV incidence and annual HSV-2 inci-
dence/prevalence, but data were sparse and 95% CIs
wide. Adjusted analyses found modest associations, that
is, HIV incidence in men with overall HSV-2 incidence
and HIV incidence in women with HSV-2 incidence in
men in the previous year. Given the strong association
between HIV incidence and HSV-2 at the individual level,
this result is unexpected. It is possible that there was
insufficient variation in annual HIV incidence or HSV-2
prevalence and incidence to demonstrate an association.
It appears that modest changes in prevalence or incidence
of HSV-2 are likely to have little effect on annual HIV
incidence in the short term. It may take several years
before any changes in HSV-2 epidemiology affect HIV
incidence as shown by the modelling studies (White et al.
2008; Freeman et al. 2009). Also, in this ecologic study
design, population-level data may have failed to ade-
quately represent individual characteristics thereby failing
to demonstrate the association seen at individual-level
analyses (Haneuse & Bartell 2011).
Limitations
Selection bias arising both from lack of follow-up of
HIV results and from loss to follow-up due to out-
migration or non-participation cannot be completely
excluded. Even in this long-standing study, median
follow-up time for participants followed for seroconver-
sion was only about 4 years. About 22% of participants
eligible for follow-up for HIV seroconversion did not
have results after their first known HIV-negative result.
As compared to the participants included in the inci-
dence analysis, the participants excluded because of lack
of follow-up HIV results, were more likely to be female,
HSV-2 positive and previously married. As these charac-
teristics are associated with a higher HIV incidence rate,
the estimated incidence may be an underestimate. How-
ever, these participants (excluded because of lack of fol-
low-up HIV results) were also more likely to be younger,
Muslims and never married – all of whom tend to have
lower HIV incidence. Therefore, the overall effect of the
differences in distribution in the characteristics of partici-
pants followed for HIV seroconversion and those
excluded because of lack of follow-up HIV results may
have been minimal.
In summary, over the study period, declines in HIV
incidence were seen in men but not in women. There is
need for renewed vigilance for prevention efforts. Known
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prevention methods such as condom promotion, promo-
tion of abstinence and faithfulness and STI treatment
should be renewed, as well as adoption of newer methods
such as voluntary medical male circumcision and early
HAART in serodiscordant couples. Further, assuming a
causal relationship, 50–75% of new HIV infections in
this study population are attributable to prevalent HSV-
2. An intervention that effectively prevents acquisition of
HSV-2 or suppresses HSV-2 reactivation may help pre-
vent many new HIV infections in populations similar to
this. Effort to develop an effective HSV-2 intervention
should be strongly supported despite lack of efficacy of
previous RCTs.
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